Pharmacy, pharmacology & toxicology Cardiovascular & respiratory systems
Author, co-author :
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Language :
English
Title :
Prevention of cardiovascular disease: plea for a rationale use of diet and lipid-lowering drugs.
Task Force Report. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19: 1434-503.
Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
Clemmer KF, Binkoski AE, Coval SM, Zhao G, Kris-Etherton PM. Diet and drug therapy: a dynamic duo for reducing coronary heart disease risk. Curr Ather Rep 2001; 3: 507-13.
Heller FR. Prevention of cardiovascular events by hypolipidemic therapy: evidence-based medicine criteria. Acta Clin Belg 1999; 54: 299-301.
Kreisberg RA, Oberman A. Lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies. J Clin Endocrinol Metab 2002; 87: 423-37.
Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J 2003; 24: 225-48.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals. Lancet 2002; 360: 7-22.
Devroey D, Willem B. An analysis of first authorisations for lipid-lowering drugs in Belgium. Acta Clin Belg 2003; 58: 152-8.
Sever PS, Dahlöf B, Poulter NR, et al for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-72.
British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. BMJ 2000; 320: 705-8.
Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomised controlled trial. JAMA 2001; 285: 1711-8.
Scheen AJ, Kulbertus H. Prévention cardio-vasculaire par les statines: faut-il encore doser le cholestérol? Rev Med Liège 2003; 58.
